On September 5, 2024, the Canadian Agency for Drugs and Technologies in Health (CADTH) officially became Canada’s Drug Agency (CDA).
CDA maintains and expands on CADTH’s mandate and functions, while “developing new programs focused on appropriate use, data and analytics, and system coordination and alignment.”
The announcement also provided an update on CDA’s strategic plan and introduced members for the Appropriate Use Advisory Committee. The mandate of the Committee includes advising CDA and providing recommendations for appropriate use strategy and programming.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.